NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES INC (NBIX): 12 pipeline candidates · 13 upcoming catalysts · ~8 mo cash runway · 29 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
7.8 months
D/E 0.44 · 3% dilution
Lead: Phase 3
12 candidates
13 upcoming, next in ~378d
0 buys · 20 sells (180d)
A transparent, data-derived signal for NEUROCRINE BIOSCIENCES INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$16.0B
Cash
$274.5M
Quarterly Burn
$614.7M
Runway
7.8 mo
Revenue
$814.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| chronocort | Phase 3 |
| crinecerfont | Phase 3 |
| efmody | Phase 2 |
| luvadaxistat | Phase 2 |
| nbi-1065845 | Phase 3 |
| nbi-1065890 | Phase 3 |
| nbi-1070770 | Phase 2 |
| nbi-1117568 | Phase 3 |
| nbi-1117570 | Phase 3 |
| nbi-827104 | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (13)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
691
Total value held
$12.84B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,385,607 | $1.76B |
| vanguard capital management llc | 9,023,808 | $1.19B |
| dodge & cox | 5,461,037 | $719.4M |
| aqr capital management llc | 4,938,967 | $650.7M |
| vanguard portfolio management llc | 4,726,344 | $622.6M |
| state street corp | 4,354,526 | $573.7M |
| two sigma investments, lp | 3,060,570 | $403.2M |
| renaissance technologies llc | 2,418,897 | $318.7M |
| geode capital management, llc | 2,136,672 | $280.8M |
| bnp paribas asset management holding s.a. | 1,493,813 | $196.8M |
Showing top 10 of 691 institutional holders of NEUROCRINE BIOSCIENCES INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NEUROCRINE BIOSCIENCES INC's pipeline?
NEUROCRINE BIOSCIENCES INC (NBIX) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEUROCRINE BIOSCIENCES INC's lead drug candidate?
NEUROCRINE BIOSCIENCES INC's most advanced tracked candidate is chronocort (Phase 3) for Congenital Adrenal Hyperplasia.
What is NEUROCRINE BIOSCIENCES INC's next catalyst?
NEUROCRINE BIOSCIENCES INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-106584" — expected July 1, 2027.
What is NEUROCRINE BIOSCIENCES INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEUROCRINE BIOSCIENCES INC has approximately 7.8 months of cash runway.
What is NEUROCRINE BIOSCIENCES INC's market capitalization?
NEUROCRINE BIOSCIENCES INC's market capitalization is approximately $16.0B.
Get the full picture on NEUROCRINE BIOSCIENCES INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.